Get the Stockscreener App
1.77
7.81%
-0.15
Pre-market:
1.65
-0.12
-6.78%
Moleculin Biotech Inc stock is traded at $1.77, with a volume of 5.58M.
It is down -7.81% in the last 24 hours and down -5.85% over the past month.
Moleculin Biotech Inc is a clinical stage pharmaceutical company focused on the development of a broad portfolio of drug candidates for the treatment of resistant tumors and viruses. The company's Annamycin program is a next-generation anthracycline designed to avoid multidrug resistance mechanisms with little to no cardiotoxicity.
See More
Previous Close:
$1.92
Open:
$1.82
24h Volume:
5.58M
Relative Volume:
1.39
Market Cap:
$7.36M
Revenue:
-
Net Income/Loss:
$-29.77M
P/E Ratio:
-0.1157
EPS:
-15.2954
Net Cash Flow:
$-24.23M
1W Performance:
+321.43%
1M Performance:
-5.85%
6M Performance:
-26.25%
1Y Performance:
-76.28%
1-Day Range:
$1.62
$2.22
1-Week Range:
$0.57
$3.6499
52-Week Range:
$0.3975
$10.35
Moleculin Biotech Inc Stock (MBRX) Company Profile
Name
Moleculin Biotech Inc
Sector
Industry
Phone
713-300-5160
Address
5300 MEMORIAL DRIVE, HOUSTON, TX
Compare MBRX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MBRX
Moleculin Biotech Inc
|
1.77 | 7.36M | 0 | -29.77M | -24.23M | -15.30 |
|
VRTX
Vertex Pharmaceuticals Inc
|
471.76 | 121.14B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
685.66 | 74.96B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
640.14 | 38.90B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
250.51 | 32.43B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
119.58 | 28.67B | 3.30B | -501.07M | 1.03B | -2.1146 |
Moleculin Biotech Inc Stock (MBRX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-12-25 | Downgrade | Maxim Group | Buy → Hold |
| Jul-18-22 | Resumed | Oppenheimer | Outperform |
Moleculin Biotech Inc Stock (MBRX) Latest News
MGO Global, Moleculin Biotech, and Sacks Parente Golf Lead Penny Stock Surge - PUNE.NEWS
Moleculin Announces FDA Guidance for MIRACLE Trial Acceleration in Relapsed or Refractory AML - DocWire News
Biotech Stocks To Keep An Eye OnFebruary 13th - MarketBeat
StockNews.com Begins Coverage on Moleculin Biotech (NASDAQ:MBRX) - Defense World
Moleculin Biotech (NASDAQ:MBRX) Enters Into Warrant Exercise Inducement Agreement - Defense World
Moleculin Biotech Receives FDA Guidance for Phase 3 Trial on Annamycin-Cytarabine Combination - Defense World
Moleculin Biotech stock hits 52-week low at $0.5 By Investing.com - Investing.com Australia
Moleculin Biotech Expects to Raise $5.8 Million From Exercise of Warrants -February 13, 2025 at 01:33 pm EST - Marketscreener.com
Why Is Blood Cancer Focused Moleculin Biotech Stock Trading More Than 400% On Thursday? - Benzinga
Moleculin Biotech secures $5.8 million from warrant exercise - Investing.com
Stock market news: Moleculin Biotech +583.33%, Cloudastructure +105.68% among top gainers during midday trading - Business Upturn
Stock market news: Tantech Holdings declined by 97.05% while Moleculin Biotech surged by 590.48% during midday trading - Business Upturn
Moleculin Secures Critical $5.8M Funding: Strategic Warrant Deal Doubles Future Potential - StockTitan
Moleculin Biotech gains approval for enrolment in trial of AML therapy in Ukraine - MSN
Moleculin (MBRX) Stock Rallies On Positive Regulatory Developments - Stocks Telegraph
Moleculin's Phase 3 AML trial gets FDA nod for size reduction - Investing.com
Stock market today: Moleculin Biotech +388.10%, Alpha Modus Holdings +156.52% among top gainers in early trading - Business Upturn
Stock market today: Tantech Holdings declined by 97.39% while Moleculin Biotech surged by 354.76% in early trading - Business Upturn
Moleculin Biotech Gets FDA Nod for Phase 3 Trial - TipRanks
Moleculin Biotech receives positive FDA guidance for acceleration of AML trial - TipRanks
Moleculin Receives Positive FDA Guidance For Its Trial For R/R Acute Myeloid Leukemia - Marketscreener.com
FDA Accelerates Game-Changing Leukemia Treatment Trial: Moleculin's Non-Cardiotoxic Solution Shows Promise - StockTitan
GLP-1 Drugs Drive Growth for Eli Lilly. Is the Stock a Buy? - AOL
Moleculin Biotech (NASDAQ:MBRX) Receives First Country Regulatory Approval in Europe for Phase 3 Clinical Trial Protocol for Annamycin Combination - Defense World
Moleculin Biotech stock hits 52-week low at $0.5 - Investing.com India
Moleculin Announces First European Approval for Phase 3 AML Trial By Investing.com - Investing.com Nigeria
Moleculin Biotech Enters into Waiver and Consent Agreement with Investor - Defense World
The Significance of Moving Averages in Moleculin Biotech Inc Inc. (MBRX) Price Performance - The InvestChronicle
Moleculin Announces First European Approval for Phase 3 AML Trial - MSN
MBRX’s price-to-free cash flow ratio: What it means for investors - US Post News
Moleculin Receives First Country Approval in Europe to Begin Recruiting for the MIRACLE Phase 3 R/R Acute Myeloid Leukemia (AML) Pivotal Trial - The Malaysian Reserve
Moleculin Biotech Receives Approval in Ukraine to Start Recruiting for Acute Myeloid Leukemia Phase 3 Trial - Marketscreener.com
Moleculin Biotech Gains European Approval for Phase 3 Trial - TipRanks
Moleculin Biotech receives first approval in Europe for AML trial recruiting - TipRanks
Moleculin Receives First Country Approval In Europe To Begin Recruiting For Phase 3 R/R Acute Myeloid Leukemia Trial - Marketscreener.com
Moleculin Biotech (MBRX) First Country Approval in Europe to Begin Recruiting for the MIRACLE Phase 3 R/R Acute Myeloid Leukemia (AML) Pivotal Trial - StreetInsider.com
Major Milestone: Moleculin (MBRX) Secures Critical European Green Light for Groundbreaking AML Treatment Trial - StockTitan
Moleculin Biotech reaches agreement to amend investor warrants By Investing.com - Investing.com Australia
StockNews.com Initiates Coverage on Moleculin Biotech (NASDAQ:MBRX) - Defense World
Moleculin Biotech reaches agreement to amend investor warrants - MSN
Moleculin Biotech Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement - Quantisnow
Closing Bell Recap: Moleculin Biotech Inc (MBRX) Ends at 0.84, Reflecting a -15.27 Downturn - The Dwinnex
MBRX stock touches 52-week low at $1.46 amid sharp yearly decline - MSN
Pediatric Brain Tumors Pipeline 2024: Latest FDA Approvals, - openPR
Moleculin Biotech (NASDAQ:MBRX) CEO Participates in Virtual Investor Segment: 8-K Filing Reveals - Defense World
Moleculin Biotech (NASDAQ:MBRX) CEO Participates in Virtual Investor “What this Means” segment – 8-K Filing News - Defense World
Comparing Biora Therapeutics (NASDAQ:BIOR) and Moleculin Biotech (NASDAQ:MBRX) - Defense World
Moleculin Biotech Shares Updates on MIRACLE Trial - TipRanks
Amendment: Moleculin Biotech Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits - Quantisnow
Moleculin Biotech Launches MIRACLE Study for AML - TipRanks
Moleculin Participates in Virtual Investor "What This Means" Segment – Company Announcement - Financial Times
Moleculin Biotech Inc Stock (MBRX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.79%
3.04%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):